Where does NeuroPace, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), NeuroPace, Inc. ranks #3,354 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does NeuroPace, Inc. hold?

NeuroPace, Inc. holds 111 US utility patents granted between 2015 and 2025, spanning 17 technology areas.

What is NeuroPace, Inc.'s Innovation Score?

NeuroPace, Inc. has an Innovation Score of 45.2 out of 100 (top 24% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does NeuroPace, Inc. focus on?

NeuroPace, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 96 patents, ranking #36 of 1,943 assignees active in that subclass. Grants appear in 17 CPC subclasses total.

Is NeuroPace, Inc.'s patent grant rate increasing or decreasing?

NeuroPace, Inc.'s recent grant velocity is -60% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for NeuroPace, Inc.'s patents?

NeuroPace, Inc.'s patents average 15.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the NeuroPace, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

NeuroPace, Inc.

USPTO PatentsView assignee record - 111 granted patents across 17 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Neuropace ranks #3,354 of 49,997 tracked US assignees by granted-patent volume, with 111 patents across 17 technology areas.

#3,354
of 49,997 US assignees by volume: Top 24%
by Innovation Score (45.2/100): 15.4
avg claims per patent: -60%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3354 · US Corporation #3,354 · 111 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MID 111 grants
TOP-DECILE #3,354/49,997
PHOTO-FINISH Kulicke and Soffa…
CPC-FOCUS A61N · 17 areas
INNOV-PAR 45.2/100
CLAIMS-RICH 15.4 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -60% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Kulicke and Soffa Industries, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Neuropace’s 45.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 16.3 pts (36%) Velocity 5.1 pts (11%) Breadth 14.6 pts (32%) Claim depth 9.2 pts (20%)

Qualcomm Incorporated · highest

85
Complete Genomics · near

45
MetaSwitch Networks · near

45
NeuroPace · this assignee

45
Pratt Retail… · near

45
Unisantis Singapore… · near

45
3D Lighting… · lowest

7

What this shows Neuropace's Innovation Score is 45.2/100 (top 24% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Neuropace?

Each dot is one of Neuropace’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neuropace’s own 15.4 claims/patent is ABOVE the 14.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Neuropace vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Neuropace's grants concentrate

NeuroPace, Inc. is a focused PatentsView assignee: 17 CPC subclasses with 86.5% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2016 (23 grants) versus a trough of 5 in 2021. By volume, Neuropace sits between Kulicke and Soffa Industries, Inc. and Sagemcom Energy & Telecom SAS.

Neuropace's three-year grant acceleration

From 2019–2021 to 2022–2024, NeuroPace, Inc. moved from 25 to 19 grants (0.76x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,960. See the growth leaderboard.

Kulicke and Soffa…

111
Macneil IP

111
Musc Foundation f…

111
Millerknoll

111
PTC Therapeutics

111
ROM

111
S V V Technology…

111
Sagemcom Energy &…

111
Neuropace ◀

111

What this shows NeuroPace holds 111 patents at rank #3,354, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near NeuroPace

By rank, the assignees closest to #3,354 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in NeuroPace's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for NeuroPace, neither rank-band nor same-CPC leaders (those blocks stay above). In A61N (Electrotherapy), NeuroPace ranks #36 of 1,943 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (45 here).

MetaSwitch Networks Ltd. 45 Pratt Retail Specialties, LLC 45 Unisantis Electronics Singapore PTE. Ltd. 45 Complete Genomics, Inc. 45

Similar claim depth

Nearest assignees by average claims per patent (15.4 here).

MultiDimension Technology Co., Ltd. 15.4 avg Liebherr-werk Ehingen GMBH 15.4 avg Electrolux Home Products Corporation N. V. 15.4 avg TCL China Star Optoelectronics Technology Co., Ltd. 15.4 avg

Neuropace's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

NeuroPace, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	18	16.2%
2016	23	20.7%
2017	13	11.7%
2018	7	6.3%
2019	14	12.6%
2020	6	5.4%
2021	5	4.5%
2022	5	4.5%
2023	9	8.1%
2024	5	4.5%
2025partial year	6	5.4%

Which technologies does NeuroPace, Inc. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 96

A61B - DIAGNOSIS; SURGERY; Identification 67

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 18

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 15

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 8

G06F - Electric Digital Data Processing 7

G06N - Computing Arrangements Based ON Specific Computational Models 6

H04W - Wireless Communication Networks 4

H01R - Electrically-conductive CONNECTIONS; Structural Associations OF A Plurality OF Mutually-insulated Electrical Connecting ELEMENTS; Coupling DEVICES; Current Collectors 3

H01Q - Antennas, i.e. Radio Aerials 3

H04Q - Selecting 2

G06V - Image OR Video Recognition OR Understanding 2

H04L - Transmission OF Digital Information, e.g. Telegraphic Communication 2

H05K - Printed CIRCUITS; Casings OR Constructional Details OF Electric APPARATUS; Manufacture OF Assemblages OF Electrical Components 1

A63F - Card, Board, OR Roulette GAMES; Indoor Games Using Small Moving Playing BODIES; Video GAMES; Games NOT Otherwise Provided FOR 1

Top 15 of 17 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

NeuroPace, Inc.'s patent record in context - here's where to go next.

NeuroPace, Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 86.5% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #3,354 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare NeuroPace, Inc. against Kulicke and Soffa Industries, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.